ACHE and status epilepticus: There were no known neuroprotective agents that could be administered systemically against soman-induced neuropathology that weren’t also anticonvulsants, drugs that stop/attenuate Status epilepticus, which in turn reduces the brain damage [40,87,95,96,97] or AChE reactivators for those enzyme molecules that were not aged [75,98,99] [NMDA receptor antagonists are not included here due to their adverse effects and the unlikelihood of FDA approval].